Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Upcoming Result Date: May 04, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Ajanta Pharma Ltd (AJANTPHARM) is currently trading at 2,791.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ajanta Pharma is a specialty pharmaceutical formulation company focused on Branded Generics across India, Asia and Africa, complemented by a selective US generics business and institutional antimalarial supplies; it develops, manufactures and markets finished dosage formulations from seven manufacturing facilities with an advanced R&D centre and a large front-end salesforce in emerging markets. The business mix is heavily skewed to Branded Generics (71% of 9M FY2026 sales of Rs. 3,995 crore), with India (31%), Asia (23%) and Africa (17%) the primary markets; Ajanta emphasizes chronic therapies, claims ~50% of products are first-to-market, manages 500+ brands and deploys nearly 6,000 medical representatives globally. Financially Ajanta delivered resilient growth with 9M FY2026 consolidated revenue of Rs. 4,031 crore (16% year-on-year), adjusted EBITDA margin around 28% and net profit margin near 20%; US generics accelerated strongly with a 46% year-on-year rise in 9M revenues, driving much of the recent uplift in consolidated performance. The company’s R&D and manufacturing capabilities are key advantages: over 850 scientists, sustained R&D spend of about 5% of revenue, 50 active ANDAs with 19 pending approvals, and seven plants including two USFDA-approved facilities; strategic priorities emphasise new product launches, market share gains, country expansion, expense optimisation and digitalisation. Near-term headwinds include lower institutional antimalarial procurement in Africa and elevated receivable days (114 days in 9M FY2026) which reduced cash conversion to 36% for the period; management continues high cash payout history while balancing investment in launches and selective US filings to sustain growth.
Over the past 52 weeks, Ajanta Pharma Ltd has traded between a low of ₹2,335.00 and a high of ₹3,158.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ajanta Pharma Ltd has a market capitalization of approximately 34,930.75. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ajanta Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.68 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 34,930.75 Cr, Ajanta Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ajanta Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ajanta Pharma Ltd is 35.68. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The inspection conducted from 13 April to 21 April 2026 concluded with the issuance of a Form 483 containing five observations.
The 'Biopharma Shakti' initiative is the most significant announcement. With a ₹10,000 crore outlay, it aims to make India a global biopharma hub, supporting Ajanta's long-term strategy to move into higher-value products like biologics and biosimilars.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Earnings Conference Call
Ajanta Pharma will release audited Q4 FY2026 financial results on 5 May 2026 and host an earnings conference call at 16:30 IST; transcript and playback will be available on the company website.
Earnings Conference Call
Ajanta Pharma will release audited Q4 FY2026 financial results on 5 May 2026 and host an earnings conference call at 16:30 IST; transcript and playback will be available on the company website.
Board Meeting Notice
Ajanta Pharma will hold a board meeting on 5 May 2026 to consider and approve consolidated and standalone audited financial results and financial statements for the quarter and year ended 31 Mar 2026.
Bearish
3
Neutral
8
Bullish
3
Bearish
26
Neutral
8
Bullish
12
Bearish
23
Neutral
0
Bullish
9
Ajanta Pharma is a specialty pharmaceutical formulation company focused on Branded Generics across India, Asia and Africa, complemented by a selective US generics business and institutional antimalarial supplies; it develops, manufactures and markets finished dosage formulations from seven manufacturing facilities with an advanced R&D centre and a large front-end salesforce in emerging markets.
The business mix is heavily skewed to Branded Generics (71% of 9M FY2026 sales of Rs. 3,995 crore), with India (31%), Asia (23%) and Africa (17%) the primary markets; Ajanta emphasizes chronic therapies, claims ~50% of products are first-to-market, manages 500+ brands and deploys nearly 6,000 medical representatives globally.
Financially Ajanta delivered resilient growth with 9M FY2026 consolidated revenue of Rs. 4,031 crore (16% year-on-year), adjusted EBITDA margin around 28% and net profit margin near 20%; US generics accelerated strongly with a 46% year-on-year rise in 9M revenues, driving much of the recent uplift in consolidated performance.
The company’s R&D and manufacturing capabilities are key advantages: over 850 scientists, sustained R&D spend of about 5% of revenue, 50 active ANDAs with 19 pending approvals, and seven plants including two USFDA-approved facilities; strategic priorities emphasise new product launches, market share gains, country expansion, expense optimisation and digitalisation.
Near-term headwinds include lower institutional antimalarial procurement in Africa and elevated receivable days (114 days in 9M FY2026) which reduced cash conversion to 36% for the period; management continues high cash payout history while balancing investment in launches and selective US filings to sustain growth.
Pharmaceuticals & Biotechnology
Pharmaceuticals
34,931 Cr
Low Risk
35.7
32.2
1.9
8.1
3,158.20
2,335.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2451.80 | 41,114 Cr | 40.80 | 24.08 | 2.23 | 55.94 | 74.64 | 27.86 | ||
1439.00 | 37,478 Cr | 40.13 | 5.05 | 0.27 | 13.33 | 17.89 | 7.73 | ||
2895.85 | 34,931 Cr | 35.68 | 8.10 | 1.00 | 22.56 | 27.85 | 17.89 | ||
1993.00 | 31,998 Cr | 43.15 | 8.41 | 0.75 | 18.88 | 25.16 | 16.00 | ||
1680.70 | 30,187 Cr | 36.63 | 6.37 | 0.19 | 16.72 | 19.37 | 9.53 | ||
1740.05 | 29,362 Cr | 33.84 | 3.07 | 1.01 | 8.27 | 12.46 | 7.18 | ||
1348.20 | 22,869 Cr | 1021.14 | 5.01 | 0.00 | 1.54 | 4.05 | -0.12 | ||
| Median: 7 Co. | — | 1740.05 | 31,998 Cr | 40.13 | 6.37 | 0.75 | 16.72 | 19.37 | 9.53 |
